METABOLIX, INC. (NASDAQ:MBLX) Files An 8-K Changes in Registrant’s Certifying Accountant
Item 4.01 Changes in Registrant’s Certifying Accountant
|
Item 9.01 Financial Statements and Exhibits.
|
|
Index to Exhibits
|
|
Exhibit 16.1
|
Committee of the Board of Directors (the “Audit Committee”)
dismissed PricewaterhouseCoopers LLP (“PwC”) as the Company’s
independent registered public accounting firm and appointed RSM
US LLP (“RSM”) as the Company’s new independent registered
public accounting firm. PwC has served as the Company’s
independent registered public accounting firm since 1996.
statements for the fiscal years ended December 31, 2015 and 2014
contained no adverse opinion or disclaimer of opinion and were
not qualified or modified as to audit scope or accounting
principles, except that the reports for both years contained a
paragraph stating that there was substantial doubt about the
Company’s ability to continue as a going concern.
subsequent period through January 3, 2017, the date of PwC’s
dismissal, there were no disagreements with PwC on any matter of
accounting principles or practices, financial statement
disclosure, or auditing scope or procedure, which disagreements,
if not resolved to the satisfaction of PwC, would have caused PwC
to make reference to the subject matter of the disagreements in
their reports. During the fiscal years ended December 31, 2015
and 2014 and the subsequent period through January 3, 2017, there
have been no reportable events (as defined in Regulation S-K
304(a)(1)(v)).
the subsequent interim period through January 3, 2017, the date
of PwC’s dismissal, neither the Company, nor anyone on its
behalf, consulted RSM regarding either (i) the application of
accounting principles to a specific transaction, either completed
or proposed; or the type of audit opinion that might be rendered
on the registrant’s financial statements, and no written report
or oral advice was provided to the Company that was an important
factor considered by the Company in reaching its decision as to
an accounting, auditing, or financial reporting issue; or (ii)
any matter that was either the subject of a disagreement (as
defined in paragraph 304(a)(1)(iv) of Regulation S-K and the
related instructions) or a reportable event (as described in
paragraph 304(a)(1)(v) of Regulation S-K).
provided PwC with a copy of the statements set forth above prior
to the time this Current Report on Form 8-K was filed with the
Securities and Exchange Commission (“SEC”). The Company
requested that PwC furnish the Company with a letter addressed to
the SEC stating whether PwC agrees with the above statements. PwC
has furnished the requested letter, and it is attached as an
exhibit to this report.
|
Exhibit
|
|||
|
No.
|
Description
|
||
|
16.1
|
|
Letter from PricewaterhouseCoopers LLP dated January 5,
2017. |
About METABOLIX, INC. (NASDAQ:MBLX)
Metabolix, Inc. is an advanced biomaterials company. The Company operates through the business of developing and commercializing technologies for the production of polymers and chemicals in microbes and plants segment. The Company is focused on delivering solutions to the plastics industry. The Company has its operations in the microbial genetics, fermentation process engineering, chemical engineering, polymer science, plant genetics and botanical science. The Company is focused on a family of biopolymers found in nature called polyhydroxyalkanoates (PHAs), which occur naturally in living organisms and are chemically similar to polyesters. The Company is also focusing on applications where the performance, biodegradability, biocontent and other attributes of its PHA biopolymers provide functional advantages, such as biodegradation, required by such applications, including PHA resins for molded articles and films, as well as PHA latex and other PHA coatings for paper and cardboard. METABOLIX, INC. (NASDAQ:MBLX) Recent Trading Information
METABOLIX, INC. (NASDAQ:MBLX) closed its last trading session up +0.010 at 0.370 with 110,014 shares trading hands.